TREATING PATIENTS DIAGNOSED WITH PANCREATIC DUCT ADENOCARCINOMA WITH USING EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR MONOCLONAL ANTIBODIES

摘要

FIELD: medicine.;SUBSTANCE: group of inventions refers to cancer immunotherapy, particularly pancreatic duct adenocarcinoma (PDAC). What is presented are agents and methods of treating a population of patients suffering PDAC tumors expressing a wild-type KRAS protein. Embodiments of the invention include administering nimotuzumab to a patient with PDAC expressing a wild-type KRAS having a sequence, corresponding to SEQ ID NO: 7 or SEQ ID NO: 24, and does not contain a mutation in amino acid residue of codon G12. Method may involve addition of other anticancer agents. Also disclosed is a method of predicting the immunity of a patient suffering PDAC, to treating with nimotuzumab based on the presence of a KRAS mutation in the tumor; wherein the presence of a KRAS mutation in the amino acid residue of the G12 codon of SEQ ID NO: 7 or SEQ ID NO: 24 indicates that said patient will be non-responsive to nimotuzumab treatment.;EFFECT: group of inventions enables increasing the survival rate of PDAC patients.;23 cl, 4 dwg, 1 tbl, 2 ex